RT Journal Article
SR Electronic
T1 Three Drugs Approved for Urothelial Carcinoma by FDA
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
SP 659
OP 660
DO 10.1158/2159-8290.CD-NB2017-071
VO 7
IS 7
YR 2017
UL http://cancerdiscovery.aacrjournals.org/content/7/7/659.abstract
AB The FDA has approved one PD-1 checkpoint inhibitor, pembrolizumab, and two PD-L1 checkpoint inhibitors, avelumab and durvalumab, to treat metastatic urothelial carcinoma in patients whose disease continues to progress despite platinum-based chemotherapy. This brings the total number of checkpoint inhibitors for the disease to five, prompting questions about how best to use them.